Thank you for submitting your manuscript for consideration by The EMBO Journal. It has now been seen by three referees, whose comments are enclosed below. As you will see, the referees vary in their degree of enthusiasm: thus, while referee 1 is overall supportive of publication, both referees 2 and 3 do not find the manuscript suitable for EMBO Journal. In general, the referees can see the potential interest in your finding that the HOPS complex specifically protects trans-SNARE complexes from disassembly, while allowing disassembly of cis-SNARE complexes. However all three also criticise that it currently remains unclear how the HOPS complex might differentially recognise trans-vs. cis-complexes. In the opinion of both referees 2 and 3, such detailed mechanistic insight would be essential for us to consider your manuscript further for publication in the EMBO Journal.
complexes from premature disassembly by Sec17/Sec18. The results suggest that HOPS can preferentially protect trans SNARE complexes relative to cis SNARE complexes. This would represent a novel role for a tethering complex and therefore would be of significant interest to those in the membrane traffic field. While the paper makes excellent use of the many tools they have developed over the years, in the end I am still concerned about a key result and the mechanism of inhibition by HOPS. 2. The other major issue is the question of mechanism. How do the authors envision that HOPS can distinguish cis SNARES from trans SNARES? The cytoplasmic helical bundle should be the same. The only difference should lie in the orientation of this bundle with respect to the membrane (s) . Can the authors demonstrate preferential binding of HOPS to trans SNARES?
Otherwise, I have a few technical or minor issues:
3. Regarding Fig1D, they never discuss lanes 10 and 11. Either discuss these in the text or delete them.
Regarding Fig 2 the legend describes panel C before panel B and never says what FT stands for.
This legend does not explain the experiment clearly. I had to go back and forth between the text and the legend to understand it. There is much more Nyv1 present in reaction A compared to reaction B. Why? It is unnecessarily confusing to refer to the two reaction conditions as A and B and then label the panels A, B and C. 7. Figure 5 shows some small but statistically significant effects that are in conflict with the authors' claims. In panel A, lane 8, SNARE complex levels drop despite the presence of HOPS. The same effect is seen in panel B, lane 8 compared to lane 5. Strangely, in panel B lane 7, SNARE complex levels appear to rise in response to S17/18. I suspect the error bars are too small or something else is going on here.
Resubmission 15 March 2010
Enclosed is our revised manuscript EMBOJ-2009-72828. Having discussed with you by phone a possible resubmission of our study, we have addressed the reviewers' comments with direct, new experiments, substantially strengthening the paper. Our new data show directly that HOPS protection of the trans-SNARE complex relies on the integrity of the 2 apposed, docked bilayers, the defining feature of trans-interactions, that this protection entails specific recognition between HOPS and SNARES, and that this protection is seen on the intact, isolated organelle as well as with the chemically-defined reconstituted system. Other reviewer concerns are directly addressed by succinct presentation of the facts that HOPS is conserved from yeast to humans (where mutations cause disease), that it is part of the family of large tethering complexes which act at each organelle, and that a substantial literature about the effects of NSF and SNAP may be explicable by SNAREcomplex protection effects as we present here. We trust that the manuscript is now ready for The EMBO Journal.
With thanks for your kind patience, and best regards, Referee #1 (Remarks to the Author):
This paper continues the tradition in the Wickner laboratory of studying the role of the HOPS complex in yeast vacuole fusion. The HOPS complex contains as a critical component the SM protein VPS33, which likely is a co-factor in catalyzing fusion with SNARE proteins. The present paper makes the important observation that the HOPS complex protects trans-but not cis-SNARE complexes from NSF-mediated disassembly. My only recommendation for this paper would be to try to dive at least a little bit into the mechanisms involved -is this a sterical inhibition, or is there a direct contact between Sec17/18 and the HOPS complex? How is the specificity for trans-vs. ciscomplexes achieved?
We This paper examines the effect of the HOPS complex on disassembly of the SNARE complex by Sec17p/Sec18p. The experiments are based on the use of a reconstituted in vitro fusion system with proteins involved in homotypic vacuole fusion in yeast. This system has been characterised in a very detailed manner and has similarities but also significant differences from other membrane fusion events. In particular, the HOPS complex is a specialised aspect of the vacuole fusion system. 
Specific issues
1. The authors conclude that "selective protection by HOPS may optimize vacuole fusion in the cell.", the is no evidence presented to back up the in vitro findings to support the idea that the phenomenon described has any importance in a cellular context.
We agree that, although the reconstituted proteoliposome system offers great advantage in dissecting a complex biochemical reaction, it is important to go back to the organelle to confirm the relevance of any finding. We now present new data to show that the HOPS effect is not limited to reconstituted proteoliposomes, but is also observed during the fusion of the intact organelle. Furthermore, each HOPS subunit is required in vivo for vacuole fusion, as the mutation of each of their genes yields a highly fragmented vacuole morphology ("vam" phenotype).
2. The general interest in the paper will be limited by the specialised nature of the HOPS complex in vacuole fusion. The findings do not, therefore, illuminate a general aspect of membrane fusion mechanism.
Although HOPS acts specifically at vacuole fusion, it belongs in a family of large tethering factors that are required for almost all intracellular trafficking events. Our study will thus provide important insights into the mechanism underlining the function of tethering factor in general. We apologize for not articulating this in our initial manuscript. We have added a new paragraph in the Introduction and drawn comparison to other tethering factors in the Discussion.
3. Overall the paper provides only a minor incremental advance nor are any insights provided into the mechanistic basis of the phenomenon where two forms of the SNARE complex are differentially sensitive. A further understanding of what is happening in this system would require structural approaches to the protein-protein interactions involved.
We have included new experiments which show that HOPS dependent protection of the trans-SNARE complex relies on continued integrity of the apposed bilayers (which is the defining characteristic of those SNARE complexes which are "trans") and requires HOPS association with Vam7p.
This paper addresses the role of the HOPS tethering complex in protection of trans SNARE complexes from premature disassembly by Sec17/Sec18. The results suggest that HOPS can preferentially protect trans SNARE complexes relative to cis SNARE complexes. This would represent a novel role for a tethering complex and therefore would be of significant interest to those in the membrane traffic field. While the paper makes excellent use of the many tools they have developed over the years, in the end I am still concerned about a key result and the mechanism of inhibition by HOPS.
We have included new experiments to address the reviewer's concern and the mechanism of HOPS action (see below). Thank you! We have now relabeled these figures and rewritten the figure legend to address these points.
The crux of the paper is in
5. Regarding Fig 3, panels B and C are mislabeled relative to the legend.
We've now fixed it. Thank you! 6. Regarding Fig 4, why does the level of complex go down on ice, lane 13 compared to 7.
Thank you for pointing it out! We have now added our explanation in the figure legend: Note that lane 13 measures trans-SNARE complex formation in the 1 st stage only. If the 2 nd stage reaction continues at 27°C without inhibitors, more trans-SNARE complex will form (compare lanes 13 and 7).
7. Figure 5 shows some small but statistically significant effects that are in conflict with the authors' claims. In panel A, lane 8, SNARE complex levels drop despite the presence of HOPS. The same effect is seen in panel B, lane 8 compared to lane 5. Strangely, in panel B lane 7, SNARE complex levels appear to rise in response to S17/18. I suspect the error bars are too small or something else is going on here.
The reviewer is right that in both panels A and B, there is slightly less SNARE complex in lane 8 than in lane 5. Although the difference is not statistically significant, it may indicate that HOPS inhibits but does not block trans-SNARE complex disassembly. We have clarified this in the revised manuscript. In panel B, lane 7, the level of SNARE complex does appear to rise but the P value between lanes 5 and 7 is 0.273. The error bars in all our figures represent standard error. We have now added P values on the figure to emphasize the statistically significant effects. 2nd Editorial Decision 13 April 2010
Many thanks for submitting the new version of your manuscript to the EMBO Journal. Please let me first apologise for the slight delay in getting back to you with a decision: I was out of the office last week over the Easter break. In addition, the decision on your manuscript was not a straightforward one, and I needed to consult further with the referees, and with our Chief Editor.
Your study has been seen again by all three referees, whose comments are enclosed below. As you will see, referees 1 and 3 are now supportive of publication, while referee 2 remains negativefinding that both his/her previous criticisms in vivo relevance and mechanistic insight remain. Given these contradictory reports, I have looked into the manuscript myself in detail, and have also discussed it further with my colleagues and with referee 3. Firstly, I would say that I fully appreciate that your study, by necessity, is an in vitro one, and I do not find the first criticism of referee 2 to be valid. In terms of the mechanistic insight, however, I do have a remaining concern. You provide evidence that the HOPS-dependent protection of trans-SNARE complexes relies on the integrity of opposed bilayers, and therefore propose that this is what HOPS is recognising to distinguish cisfrom trans-complexes. However, if I understand your experimental set-up correctly, your data can not exclude the possibility that Triton treatment not only disrupts the membranes, but also induces remodelling of the SNARE complex into a (cis-like) configuration that is now susceptible to Sec17/18 disassembly. I have discussed this concern further with referee 3, who agrees with this point, but is none-the-less in favour of publication of your manuscript, provided you include some discussion as to the alternative possibilities -something that referee 1 also highlights in his comments.
Like the majority of the referees, we do find the basic observation of your study to be an interesting one, but we are still concerned as to the level of mechanistic insight. I therefore wonder whether you are able to address the specific issue outlined above experimentally. If so, we would really encourage you to do so in a further revision of the manuscript. Therefore, please can you let me know whether you are able to perform any additional analysis to strengthen your proposal that it is the integrity of the opposed bilayers that is critical for the specificity of the HOPS-SNARE interaction. If so, we are happy to wait for such analysis to be completed, and to consider a revised version of the manuscript incorporating such data. If, however, this issue can not be addressed experimentally, we would be willing to consider a suitably toned down version of the manuscript, discussing the possibility of alternative explanations for the data, for publication. Please can you let me know how you would like to proceed, and also if you have any further questions or comments on the points raised here.
I look forward to your response, Best wishes, Editor EMBO Journal
REFEREE REPORTS
Referee #1 (Remarks to the Author):
I liked the paper the first time around, and I still supports its publication. I think the authors have addressed my concerns successfully, and also the concerns of the other reviewer. In my view, the major concern of reviewer #2 seems to be that vacuole fusion in yeast is too specialized to be of general interest; I personally find this concerns slightly off target, as every fusion reaction is 'specialized' for a given pair of membranes; it is as interesting to know what is special about a reaction as what is general, and at present we don't know either -although I suspect that the actions of the HOPS complex will be very general! On the other hand, I think reviewer #3 raises legitimate concerns that the authors tried to address, as best as possible with the available technology. In my view, the paper thus is acceptable for publication, with the only minor revision being to inject a note of caution into the text regarding the mechanism.
Referee #2 (Remarks to the Author):
There were a number of issues that arose from the first version of the manuscript that needed to be addressed experimentally/ 1. A need to demonstrate the relevance of the phenomenon in a cellular context. The authors have added in additional data form another in vitro assay but have still not addressed the relevance within a cellular context.
2. The paper did not provide and mechanistic insight into how two forms of the SNARE complex could be differentially sensitive. It was suggested that structural approaches would be needed to resolve this. The nerw version of the manscript still does not provide any experimental data addressing this issue. the onlt new experiment is to show that bilayer integrety is required. The major question has therefore still not been addressed.
Referee #3 (Remarks to the Author):
The authors have addressed my prior concerns regarding the fairness of the comparison between cis and trans SNARE complexes and have added a new aspect of the paper suggesting that the interaction of HOPS with the membrane is important for its activity in inhibiting the disassembly of trans SNARE complexes by Sec18.It is still a rather challenging paper to read, but I don't have any good suggestions for making it easier.
Additional Correspondence 14 April 2010
Thank you for putting such effort into helping us with this manuscript! I really appreciate it.
All eukaryotic cells are full of alpha-SNAP/Sec17p and NSF/Sec18p, which we've shown to be capable of disassembling trans-SNARE complexes and thereby blocking fusion unless something (such as HOPS for the vacuole/lysosome) interferes to protect these complexes. Thus our current finding that HOPS inhibits trans-SNARE complex disassembly, preserving trans-SNARE complexes so that they can support fusion, while not preventing cis-SNARE complexes from being disassembled so that their constituent SNAREs can be used for trans-complex assembly, is of general interest and importance for fusion reactions throughout the cell. Of course we'll only know if this is true for all SNAREs, and for each organelle's large effector tethering complex, when the matter is tested in all the other organelles, but surely EMBO Journal wants to publish the discovery, not the confirmation in other organelles! (Here, I'd do one of those typed smiley faces if I knew how...).
Now we come to the important question of how this works, just HOW does HOPS prevent Sec17p/Sec18p action on trans-SNARE complexes?! Everyone in the field (including us) believes that trans-SNARE complexes have their trans-membrane anchors "splayed out" into the 2 apposed bilayers, whereas the transmembrane anchors are together and parallel when in cis-SNARE complexes, the structure which Jahn and colleagues crystallized. Without HOPS, Sec17p/Sec18p disassembles either cis-or trans-SNARE complexes (corresponding to the membrane-splayed conformation or the membrane anchors together conformation) as we've shown here with our chemically-defined reaction and as has been shown previously on the organelle (Jun et al. 2007 ). HOPS only inhibits Sec17p/Sec18p-mediated tran-SNARE complex disassembly but, again, the underlying trans-SNARE complex was inherently sensitive to Sec17p/Sec18p when HOPS hadn't been added.
You wrote "However, if I understand your experimental set-up correctly, your data can not exclude the possibility that Triton treatment not only disrupts the membranes, but also induces remodelling of the SNARE complex into a (cis-like) configuration that is now susceptible to Sec17/18 disassembly." Excellent point!--you're right. This brings up an alternative model to explain the data: Instead of HOPS (a huge 600 kDa complex) spatially blocking the access of Sec17p/Sec18p to trans-SNARE complexes which are wedged between apposed, docked membranes, perhaps HOPS induces a subtle conformational change in the trans-SNARE complex to render it an inherently poor substrate for Sec17p/Sec18p, and Triton causes a reversal of this conformational change. We'd be happy to "tone down" our paper as you suggested by adding this to the Discussion as an alternative explanation. Perhaps our repeated use of the word "protects" with regards to HOPS action, from the title onwards, is easily taken to imply that it provides a physical barrier to Sec17p/Sec18p, which is unproven. We should substitute a more accurate description; instead of "HOPS Protects trans-SNARE Complexes from Sec17p/Sec18p-Mediated Disassembly During Fusion" (current title) we should say "HOPS Prevents the Disassembly of trans-SNARE Complexes by Sec17p/Sec18p During Fusion." "Prevents" describes it without overreaching about what's been truly proven; as you say, this is "toning it down"! If you don't mind, we'll make this modification to the paper throughout; in the title, abstract, in the Results where we present relevant aspects of the data, and in the Discussion.
Thanks.
Another good idea is that we seek another super-duper experiment to add; I'd love to (!), but the next level of understanding would require a crystal structure of the HOPS:trans-SNARE complex, an entirely different level of undertaking! Again, many thanks, and I look forward to your thoughts on this.
Additional Editorial Correspondence 14 April 2010
Thanks for getting back to me so quickly and for your detailed response. I do understand that, at this stage, further mechanistic insight would likely require structural analysis, and that this lies well beyond the scope of the current mansucript. Therefore, I agree that reworking the text to acknowledge the limitations of your approach and to discuss other possibilities is the best way forward at this point.
Your model that HOPS might induce a conformational change in the SNARE complex is certainly an interesting one and would be worth discussing alongside your favoured proposal that HOPS recognises the apposed bilayers. However, what concerned me was the rather more prosaic possibility that trans-and cis-SNARE complexes are normally in different conformations (independent of HOPS), and that HOPS could only recognise the trans-conformation. Then, in your Triton experiment, what happens is that -in addition to disrupting the bilayer -the SNARE complex reverts to its cis conformation, which now makes it a target for Sec17/18. Am I right in thinking that this could be the case? If so, it would be important to acknowledge this, as well as discussing the two interesting models you propose.
All the same, we do agree that your current finding is an interesting one, and worthy of publication in the EMBO Journal at this stage. I simply think it important that you do not overstate the mechanistic insight gained from the additional experiments included in the revision! I agree that "prevents" is probably a better term than "protects", and so if you can make these changes, as well as expand your discussion as outlined in your message and above, I think we could then go ahead and accept the manuscript. Thank you. Your point is thoughtful; we've previously published though (Collins et al., 2005) that HOPS associates with cis-SNARE complexes too; we'll be sure to add that directly now in the Discussion.
I appreciate that you've put in a lot of extra work to help us with this paper. A heartfelt Thank You!! 1st Revision -Authors' response 15 April 2010
As per our emails, Dr. Xu and I are now resubmitting the manuscript with the changes we discussed. I hope it is now ready for the EMBO Journal.
Additional Editorial Correspondence 16 April 2010
Many thanks for submitting the revised version of your manuscript. Having read through it, I am happy with the changes made to the text. However, before we can accept the study, I noticed a problem with one of the figures that needs to be dealt with. In figure 1D , in the lower panel of blots, it appears that different gels or parts of a gel have been spliced together (between lanes 5 and 6). I hope that all lanes have come from the same original blot, and it is simply that intervening lanes have been removed: this is fine, but needs to be clearly marked on the figure, and it should be stated in the figure legend how this panel has been assembled. In addition, I would ask you to send me the original scan of the blots in question: this is standard procedure and something we ask for in all such
